Skip to main content

Caledon Bioscience Inc.

Tuesday, February 27, 2024
Caledon Biosciences is a privately held, start-up founded in October 2023. Caledon owns the key assets, management and operations of a former NASDAQ listed entity, Liminal BioSciences Inc, which was recently delisted and taken private. Based in Canada with operations in the UK, we currently have a sole Seed investor, Thomvest Asset Management, and are seeking to expand our investor base, bringing in a new lead investor and potentially a small syndicate to take us to the next stage of development. Thomvest have signified an intent to invest further. Our pipeline consists of 3, GPCR-based, small molecule programs targeting inflammation, fibrosis and metabolic disease. The pipeline is preclinical, with our lead asset entering the clinic in December 2023. We believe that we represent an interesting value proposition with near-term value inflection points through upcoming data and potential for business development activity.
Bruce Pritchard, CEO - Caledon Bioscience Inc.





Website (currently under construction)

CEO/Top Company Official

Bruce Pritchard, BA, CA, FioD

Lead Product in Development

We have a pipeline of 3, small-molecule assets focused on GPCR targets implicated in inflammation, fibrosis and metabolic disease, the first of which, a selective GPR84 antagonist for NASH/NAFLD will be in the clinic before the end of this year. Our CTA has recently been submitted.

Development Phase of Primary Product


Double Helix


Supporting Bank Sponsor


Premier Sponsors

Conference Sponsors


Media Partner


Sign up for updates

Stay up-to-date on the BIO CEO and Investor Conference via email.